2013 Archived Content
Ninth Annual

Clinical and Translational Science

Strategies to Accelerate and De-Risk Clinical Development


Day 1 | Day 2 | Day 3 | Download Brochure 

Friday, February 15

8:00 am Morning Coffee


Data Integration Strategies to Support Clinical & Translational Research 

8:30 Chairperson’s Remarks

Ajay Shah, Ph.D., Director, Research Informatics Division, City of Hope

8:35 Translational Research Informatics Platform at City of Hope

Ajay Shah, Ph.D., Director, Research Informatics Division, City of Hope

City of Hope (COH) is implementing several components of its Translational Research Informatics Platform.This platform leverages COH Enterprise Data Warehouse.Natural language processing components of the platform allows for analysis of EMRs, and extraction of coded fields from these records.

9:05 Path to Develop Integrated Data for Biomarker Research

Carol Bova Hill, Ph.D., Informatics Project Leader II, Clinical Research Informatics, Duke Clinical Research Institute

Integration of data to support translational research requires rigorous understanding of data and highlights the crucial role of the Informaticist.I will outline efforts and challenges to create a robust systematic environment to support the utilization of biospecimens at DCRI.

9:35 Data Visualization in Clinical Research

Dimitris Agrafiotis, Janssen R&D, Johnson & Johnson


TessellaNEW 10:05 A Day in the Life of a Data Scientist: Improving Translational Informatics
Jamie MacPherson, Ph.D., Consultant, TessellaTranslational informatics integrates and interrogates multiple data assets across different stages in drug development; these assets are diverse in type, scale and quality.  To be efficient and effective, translational informatics projects must balance technical innovation and a practical ability to provide interpretable results. Here, we present a novel approach to translational informatics support: embedding 'Data Scientists' within drug-project teams.

10:20 Coffee Break


Molecular Profiling for Patient Selection 

10:30 Clonal Analysis and Molecular Profiling for Patient Selection

Michael Barrett, Ph.D., Associate Professor, Clinical Translational Research Division; Unit Head, Oncogenomics Laboratory, TGEN

Cancers frequently arise as a result of an acquired genomic instability and the subsequent evolution of neoplastic cells with variable genomes. Thus the behaviors of distinct clonal populations in each patient’s tumor underlie the clinical phenotypes of many cancers.

11:00 Molecular Profiling for Patient Selection: MD Anderson Perspective

Apostolia-Maria Tsimberidou, M.D., Ph.D., Associate Professor, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center

11:30 Challenges and Issues in the Clinical Execution of a Biomarker Driven Clinical Trial

Alexandra Gunchenko, Associate Director, Clinical Research, Merck

12:00 Enjoy Lunch on Your Own


Clinical Trial Specimens in Cancer Research 

1:15 Chairperson’s Remarks

1:20 Cooperative Oncology Group Banks (CGBS)

Irina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH

CGBs collect, store and distribute specimens from patients treated in phase III and large phase II NCI-funded randomized clinical trials.These well-annotated specimen collections are unique because they have associated uniform clinical, treatment, and outcome data.

1:50 The Role of the Biorepository in Cancer Clinical Trials: “From Bed to Bench”

Nilsa C. Ramirez, M.D., Director, Surgical Pathology, Pathology and Laboratory Medicine, Nationwide Children’s Hospital; Medical Director, Biopathology Center, Co-I and Lead Pathologist, TCGA BCR, The Research Institute at Nationwide Children’s Hospital

Biorepositories directly influence the outcome of translational research in clinical trials.They oversee procurement, banking, testing and distribution of quality clinical trial samples to approved investigators. The role of the biorepository in the cancer cooperative group organization is discussed.

2:20 National Breast Cancer Biobank and Oncology Research

Valerie Speirs, Ph.D., Associate Professor, Leeds Institute of Molecular Medicine, University of Leeds

2:50 The Role of the Tissue Bank in Academic Cancer CentersTeri A. Longacre, M.D., Professor of Pathology, Director, Tissue Procurement Facility, Stanford Cancer Center, Stanford, California 
The various functions of the tissue bank in academic cancer centers have increased in complexity in the last decade. In this lecture, key problem areas faced by academic cancer centers in the areas of tissue procurement, tissue distribution, quality metrics, accommodation of SPORE and other specific programmatic projects, clinical annotation, and data tracking are discussed.  In addition, the concept of a “clinical biobank” as opposed to the traditional “research  biobank” is introduced. 

3:20 Close of Conference


Day 1 | Day 2 | Day 3 | Download Brochure 


Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors